Oxidien Announces Publication of Clinical Results Demonstrating Significant Reduction in Urinary Oxalate

UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company mitigating kidney stone disease by treating secondary hyperoxaluria, announced the publication of data from a clinical study on the effectiveness of its highly potent and acid-stable Oxalate Decarboxylase (OxDC) to reduce urinary oxalate in subjects on a high oxalate diet. The study was published in Kidney360, a new addition to the American Society of Nephrology portfolio of journals.

“We are excited to see these data peer-reviewed and published as we continue to advance our secondary hyperoxaluria program in the clinic,” said Helena Cowley, president and CEO of Oxidien. “We would like to thank the investigators, staff, and volunteers for their participation and for contributing to our understanding of this Synechococcus elongatus OxDC as we work to address a significant unmet need in hyperoxaluria.”

Learn more about Oxidien Announces Publication of Clinical Results Demonstrating Significant Reduction in Urinary Oxalate.